Skip to content

Author

Zaiyang Zhang

We have 3 of 8 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Targeted gene therapy alleviates epilepsy and hyperexcitability in models of SCN2A deficiency.

Proof of principle is provided for drug-controllable KCNA1 gene therapy as a promising treatment avenue for epilepsy related to SCN2A LoF variants by normalized elevated neuronal firing and reduced spontaneous seizure burden in Scn2a-deficient mice.

Zai-Yang Zhang, Jing-Liang Zhang, Xiao-Ling Chen et al. · 0 citations
Open access Sep 2026

Gene therapy with doxycycline-controlled expression of human Kv1.1 reduces neuronal excitability and increases sociability of Scn2a-deficient mice

Overall, the successful use of an inducible AAV-mediated gene delivery system to supplement hKv1.1 expression to mitigate neuronal hyperexcitability and ameliorate social impairments in a mouse model of SCN2A-related ASD is demonstrated.

Brody A. Deming, Jing-Liang Zhang, Iuliia Vitko et al. · 1 citation
Open access Jul 2026

Epilepsy-associated SCN2A-L1342P mutation drives network hyperexcitability and widespread transcriptomic changes in human cortical organoids.

These findings demonstrate that the Nav1.2-L1342P mutation drives a multifaceted disease phenotype, including network hyperexcitability and disruption of pathways related to neuronal and synaptic functions, which advances understanding of SCN2A-related developmental and epileptic encephalopathy (DEE).

M. I. Olivero-Acosta, Morgan Robinson, Zhefu Que et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.